IDH1 and glioblastoma: However, as shown in Fig. 3d, MGMT promoter methylation was significantly associated with a prolonged overall survival in GBM IDH-wildtype (p = 0.009), while in astrocytomas IDH-wildtype (Fig. 3e) had no impact in prognosis (p = 0.555).